Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 21;11(5):e0129823.
doi: 10.1128/spectrum.01298-23. Online ahead of print.

Lugdunin production and activity in Staphylococcus lugdunensis isolates are associated with its genotypes

Affiliations

Lugdunin production and activity in Staphylococcus lugdunensis isolates are associated with its genotypes

Shih-Cheng Chang et al. Microbiol Spectr. .

Abstract

Lugdunin produced by Staphylococcus lugdunensis has been shown to have broad inhibitory activity against Gram-positive bacteria; however, lugdunin activity among S. lugdunensis isolates and its association with different agr, SCCmec, and sequence types remain unclear. We used matrix-assisted laser desorption ionization-time-of-flight mass spectrometry to identify S. lugdunensis and collected 202 S. lugdunensis samples for further assays. Agar spot tests were performed to characterize S. lugdunensis lugdunin production and activity. Multilocus sequence typing, SCCmec, and agr genotyping were performed on S. lugdunensis. In all, 91 Staphylococcus aureus strains with varying vancomycin susceptibilities were used to examine lugdunin activity in S. lugdunensis. In total, 48 S. lugdunensis strains (23.8%) were found to be oxacillin-resistant S. lugdunensis (ORSL), whereas 154 (76.2%) were classified as oxacillin-sensitive S. lugdunensis (OSSL). Moreover, 16 (33.3%) ORSL and 35 (22.7%) OSSL strains showed antibacterial activity against S. aureus. Our data showed that most lugdunin-producing ORSL strains (14/48, 29.2%) were of ST3-SCCmec V-agr II genotypes, whereas most lugdunin-producing OSSL strains (15/154, 9.7%) were of ST3-agr II, followed by ST1-agr I (10/154, 6.5%). Our data also revealed that lugdunin exhibited weak inhibitory activity against the VISA ST239 isolate. In addition, we observed that ST239 VSSA was more resistant to lugdunin than ST5, ST59, and ST45 VSSA. Taken together, our data pioneered the epidemiology of lugdunin production in S. lugdunensis isolates and revealed its association with genotypes. However, further molecular and bioinformatics investigations are needed to elucidate the regulatory mechanisms of lugdunin production and activity. IMPORTANCE Lugdunin is active against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci by dissipating their membrane potential. However, the association of lugdunin activity with the genotypes of Staphylococcus lugdunensis has not been addressed. Here, we show the high prevalence of lugdunin-producing strains among ST1 (83.3%), ST2 (66.7%), and ST3 (53.3%) S. lugdunensis. Moreover, we identified the antibacterial activity of lugdunin-producing strains against VISA and hVISA. These results shed light on the potential application of lugdunin for the treatment of drug-resistant pathogens.

Keywords: S. aureus; Staphylococcus lugdunensis; genotype; lugdunin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Representative results of lugdunin activity using agar spot test. S. aureus HG001 was used to test the anti-S. aureus activity of lugdunin. SL243 [ST24-agr I oxacillin-sensitive S. lugdunensis (OSSL)], SL163 (ST2-agr II OSSL), SL158 (ST6-agr I OSSL), and SL85 [ST3-SCCmec V-agr II oxacillin-resistant S. lugdunensis (ORSL)] were used to represent S. lugdunensis with different anti-S. aureus activity. SL118 (ST6-SCCmec II-agr I ORSL) was considered a lugdunin-negative control strain. 2,2′-dipyridyl (2-DP), a ferrous iron chelator, was added to induce lugdunin production.

References

    1. Mattar C, Edwards S, Baraldi E, Hood J. 2020. An overview of the global antimicrobial resistance research and development hub and the current landscape. Curr Opin Microbiol 57:56–61. doi:10.1016/j.mib.2020.06.009 - DOI - PubMed
    1. Yildirim O, Gottwald M, Schüler P, Michel MC. 2016. Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. Front Pharmacol 7:461. doi:10.3389/fphar.2016.00461 - DOI - PMC - PubMed
    1. Milshteyn A, Colosimo DA, Brady SF. 2018. Accessing bioactive natural products from the human microbiome. Cell Host Microbe 23:725–736. doi:10.1016/j.chom.2018.05.013 - DOI - PMC - PubMed
    1. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375:1557–1568. doi:10.1016/S0140-6736(09)61999-1 - DOI - PMC - PubMed
    1. Laux C, Peschel A, Krismer B. 2019. Staphylococcus aureus colonization of the human nose and interaction with other microbiome members. Microbiol Spectr 7. doi:10.1128/microbiolspec.GPP3-0029-2018 - DOI - PMC - PubMed

LinkOut - more resources